Navigation Links
CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
Date:11/14/2011

SAN FRANCISCO, Nov. 14, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented preclinical research results at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in San Francisco, California demonstrating that analogs of novel FAK inhibitor CFAK-C4 disrupted FAK-vascular endothelial growth factor receptor 3 (FAK-VEGFR3) interaction and inhibited pancreatic cancer tumor growth at low concentrations as single agents. The research was conducted by CureFAKtor scientists at the Roswell Park Cancer Institute in Buffalo, New York.

In the poster presentation, Development of Novel FAK Inhibitors Targeting the FAK-VEGFR3 Protein-Protein Interaction Site, CureFAKtor Chief Scientific Officer Dr. William Cance and Senior Scientist Dr. Elena Kurenova reported that oral small molecule FAK inhibitor C4 analogs, C9, C10 and C9A, administered as low dose single agents led to 40 to 60 percent reduction in pancreatic tumor growth in vivo after 30 days of treatment in mouse models. The C4 analogs displayed enhanced potency, minimum toxicity and high specificity for the target site. Abstract C124 will be presented on Tuesday, November 15 from 12:30 to 2:30 pm at West Hall, Level One, Moscone Center West.

"These preclinical results of C4 analogs inhibiting pancreatic tumor growth are very promising and add to our existing C4 data," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals. "We know that FAK protects tumors from chemotherapeutic drugs and radiation, allowing the tumor cells to resist these therapies."

CureFAKtor Pharmaceuticals recently presented preclinical research results at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain demonstrating that FAK inhi
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
2. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
3. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
4. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... ISPE—the International Society for Pharmaceutical Engineering ... as President and CEO, succeeding Nancy ... Society last fall.  Mr. Bournas takes the helm ... association industry as well as significant international experience.  ... for the expansion of its global initiatives and ...
(Date:7/29/2014)... (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at ... Lab Expo today by unveiling two booths (#1209 and ... with customers to redefine the value of the laboratory. ... they,re looking for a partner to help them maximize ... said Jack Phillips , president and CEO of ...
(Date:7/29/2014)... , July 29, 2014 Research and ... "Global Respiratory Devices Market 2014-2018" report to their ... A respiratory device is a medical device used ... having difficulty in breathing and cannot achieve adequate oxygen ... as cystic fibrosis, asthma, COPD, and ARDS require the ...
Breaking Medicine Technology:ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4Global Respiratory Devices Market 2014-2018 2
... , , TARRYTOWN, N.Y., ... will webcast its presentation at the Deutsche Bank 2009 Biotech ... is scheduled for 3:35 p.m. Eastern Time. The session ... , on the Investor Relations page. An archived version ...
... , MINNEAPOLIS, Dec. 10 Uroplasty, Inc. (NYSE ... develops, manufactures and markets innovative proprietary products to treat ... OrBIT Trial of its Urgent® PC Neuromodulation System that ... of THE JOURNAL OF UROLOGY® . The Urgent ...
Cached Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... leading pediatricians have joined our network, CarePoint Health ... and Dr. Sushma Kaki. Hundreds of highly skilled ... a comprehensive network of top doctors and practices ... specialties. This latest acquisition represents CarePoint Health’s commitment ...
(Date:7/29/2014)... Mozes HealthDay Reporter TUESDAY, ... patients with just a single dose of the hormone oxytocin ... Japanese researchers report. Known as the "love hormone," oxytocin ... between lovers, and between mothers and their children. In ... area of the brain that has long been associated with ...
(Date:7/29/2014)... Merrick, NY (PRWEB) July 29, 2014 Summer is ... whether that means enjoying a hike, swimming in a pool or ... it’s time for fleas and ticks. The Puppy Store is here ... during the summer months. , It’s almost impossible to completely keep ... can take to minimize the chances of their pets coming into ...
(Date:7/29/2014)... Bret Busacker , a partner in ... appointed to the Board of Directors for the American ... experienced business attorney with a focus on employee benefits ... wide spectrum of topics regarding equity and incentive compensation, ... His clients include public and private businesses, governmental entities, ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2
... Life-Threatening, Genetic,Disease, WASHINGTON, May 13 Alabama has ... requiring that all newborns be,screened for cystic fibrosis at ... screening program for,cystic fibrosis," said Robert J. Beall, Ph.D., ... 40 states are now screening for the,disease. With every ...
... expression of a key enzyme, vitamin D protects healthy ... lead to cancer, University of Rochester Medical Center researchers ... properties of vitamin D, said Yi-Fen Lee, associate professor ... research. Our findings reflect what we see in those ...
... patient care by recognizing quality and,safety in endoscopy, ... American Society,for Gastrointestinal Endoscopy (ASGE) announces the launch ... endoscopy, in all settings,where it is practiced in ... will recognize endoscopy units that follow the ASGE,guidelines ...
... MILLS, Md., May 13 Medifast, Inc.,(NYSE: ... today,announced that Barry B. Bondroff, CPA has been ... Senior Managing Director with SMART, a,diverse team of ... years of experience providing companies of all sizes ...
... New report provides blueprint to fight the environmental triggers ... homes, schools,playgrounds and neighborhoods are riddled with preventable asthma ... a new report released,today by PolicyLink and The California ... do to make our children,s air safer and healthier., ...
... Inc. (Nasdaq: SNSS ) today announced that Eric ... a corporate update at the upcoming Rodman & Renshaw ... on Monday, May 19,2008 at the Le Meridien Beach ... may access a webcast of the presentation by visiting,the ...
Cached Medicine News:Health News:Alabama Begins Mandatory Screening of Newborns for Cystic Fibrosis 2Health News:Vitamin D protects cells from stress that can lead to cancer 2Health News:ASGE Launches Endoscopy Unit Recognition Program 2Health News:ASGE Launches Endoscopy Unit Recognition Program 3Health News:ASGE Launches Endoscopy Unit Recognition Program 4Health News:Medifast, Inc. Names Barry B. Bondroff, CPA to Board of Directors 2Health News:Why Our Kids Can't Breathe in Our Communities 2Health News:Why Our Kids Can't Breathe in Our Communities 3
... This programmable system automates the denaturation ... procedures, and provides walk-away convenience for ... cost unit accepts a wide range ... use, and reduces hands-on time by ...
... DiffSpin Slide Spinner for technique independent ... wedge smears.,DiffSpin is a compact, quiet, ... the preparation of uniformly distributed cell ... with a start-up supply of slides ...
... systems deliver pulsed light over one smooth ... spikes (which may damage skin) that other ... sends a chilled water supply through the ... which is cooled to as low as ...
... small, quiet, high-speed centrifuge. It employs a ... results in nearly vibration- free operation. Light ... speed and full breaking in a few ... a simple push-on/ pull-off; transforming the centrifuge ...
Medicine Products: